220 related articles for article (PubMed ID: 29212421)
1. Antineoplastic chemotherapy in Jehovah's Witness patients with acute myelogenous leukemia refusing blood products - a matched pair analysis.
Wilop S; Osieka R
Hematology; 2018 Jul; 23(6):324-329. PubMed ID: 29212421
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of acute myeloid leukaemia without blood transfusion in a member of Jehovah's Witnesses].
Larsen C; Jensen MK
Ugeskr Laeger; 2011 Nov; 173(46):2960-2. PubMed ID: 22094219
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma.
Zhou L; Mohsen A; Khan MA; Guthrie T
J Chemother; 2014 Jun; 26(3):184-6. PubMed ID: 24621157
[TBL] [Abstract][Full Text] [Related]
4. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
Laszlo D; Agazzi A; Goldhirsch A; Cinieri S; Bertolini F; Rabascio C; Pruneri G; Calabrese L; Cocquio A; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):264-7. PubMed ID: 15089764
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient.
Chojnowski K; Janus A; Bliźniewska K; Robak M; Treliński J
Transfusion; 2016 Oct; 56(10):2438-2442. PubMed ID: 27385671
[TBL] [Abstract][Full Text] [Related]
6. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience.
Mazza P; Prudenzano A; Amurri B; Palazzo G; Pisapia G; Stani L; Pricolo G
Bone Marrow Transplant; 2003 Aug; 32(4):433-6. PubMed ID: 12900781
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Jehovah's Witnesses with hematological malignancies treated without transfusions - single center experience.
Drozd-Sokołowska JE; Waszczuk-Gajda A; Dwilewicz-Trojaczek J; Walesiak A; Krzyżanowska M; Paluszewska M; Wieczorek J; Jędrzejczak WW
Folia Med Cracov; 2020; 60(4):53-64. PubMed ID: 33821851
[TBL] [Abstract][Full Text] [Related]
8. Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: a two-institutional experience report.
Tenenbaum T; Hasan C; Kramm CM; Janssen G; Laws HJ; Wessalowski R; Bode U; Göbel U
Onkologie; 2004 Apr; 27(2):131-7. PubMed ID: 15138344
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute leukaemia in adult Jehovah's Witnesses.
El Chaer F; Ballen KK
Br J Haematol; 2020 Sep; 190(5):696-707. PubMed ID: 31693175
[TBL] [Abstract][Full Text] [Related]
10. [Mortality after high-risk surgery in Jehovah's Witness patients].
Habler O; Thörner M; Schmidt C; Hofmann P; Döbert U; Höhler M; Klingler S; Moog S; Oehme A; Schäufele M; Wege C; Voß B
Anaesthesist; 2019 Jul; 68(7):444-455. PubMed ID: 31236704
[TBL] [Abstract][Full Text] [Related]
11. Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.
Fujisawa S; Naito K; Matsuoka T; Kobayashi M
Int J Hematol; 2007 Jun; 85(5):418-20. PubMed ID: 17562618
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of cardiac surgery outcomes in Jehovah's versus Non-Jehovah's Witnesses.
Stamou SC; White T; Barnett S; Boyce SW; Corso PJ; Lefrak EA
Am J Cardiol; 2006 Nov; 98(9):1223-5. PubMed ID: 17056333
[TBL] [Abstract][Full Text] [Related]
13. Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia.
Kerridge I; Lowe M; Seldon M; Enno A; Deveridge S
Arch Intern Med; 1997 Aug 11-25; 157(15):1753-7. PubMed ID: 9250237
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience.
Bhaskar B; Jack RK; Mullany D; Fraser J
Heart Lung Circ; 2010 Nov; 19(11):655-9. PubMed ID: 20813584
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcome of cardiac surgery under cardiopulmonary bypass in patients who refuse transfusion: a controlled study.
Reyes Garcia A; Vega González G; Andino Ruiz R
J Cardiovasc Surg (Torino); 2018 Oct; 59(5):729-736. PubMed ID: 29616523
[TBL] [Abstract][Full Text] [Related]
16. Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness.
Arora N; Gupta A; Li HC; Sadeghi N
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567199
[TBL] [Abstract][Full Text] [Related]
17. Is There Sufficient Evidence Justifying Limited Access of Jehovah's Witness Patients to Kidney Transplantation?
Carvalho Fiel D; Nunes Ficher K; Bernardi Taddeo J; Linhares Silva K; Rosso Felipe C; Aguiar W; Daniel Braz Cardone J; Foresto RD; Tedesco-Silva H; Medina-Pestana J
Transplantation; 2021 Jan; 105(1):249-254. PubMed ID: 33350627
[TBL] [Abstract][Full Text] [Related]
18. Bloodless intensive care: a case series and review of Jehovah's Witnesses in ICU.
MacLaren G; Anderson M
Anaesth Intensive Care; 2004 Dec; 32(6):798-803. PubMed ID: 15648990
[TBL] [Abstract][Full Text] [Related]
19. "Bloodless" Neurosurgery Among Jehovah's Witnesses: A Comparison with Matched Concurrent Controls.
Hardesty DA; Doerfler S; Sandhu S; Whitmore RG; Ford P; Rushton S; LeRoux PD
World Neurosurg; 2017 Jan; 97():132-139. PubMed ID: 27641256
[TBL] [Abstract][Full Text] [Related]
20. [Physicians' perception on taking care of Jehovah's witnesses].
Gouezec H; Lerenard I; Jan S; Bajeux E; Renaudier P; Mertes PM;
Transfus Clin Biol; 2016 Nov; 23(4):196-201. PubMed ID: 27634593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
